Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lenalidomide plus docetaxel/prednisone versus placebo plus docetaxel/prednisone in metastatic castration-resistant prostate cancer
NL-OMON43687Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Lenalidomide + docetaxel + prednisone with Placebo + docetaxel + prednisone (2 arms). Primary endpoint: Overall survival. Started Apr 2010; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON43687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43687.